anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a hair dye composition, containing an amphoteric surfactant, branched chain higher alcohol and alkyl ether type nonionic surfactant together with a hair dye ingredient and excellent in gloss and touch of hair with hardly any irritation to the skin. CONSTITUTION:A hair dye composition containing (A) an amphoteric surfactant, e.g. imidazoline type, alkyl betaine or alkylamine oxide, (B) a branched higher alcohol, e.g. octyldodecanol or hexyldecanol, and (C) an alkyl ether type nonionic surfactant, e.g. polyoxyethylene alkyl ether or polyoxyethylene alkyl phenyl ether, together with a hair dye ingredient. The amounts of the respective ingredients are 1-50wt.%, preferably 5-40wt.% ingredient (A), 0.1-20wt.%, preferably 1-10wt.% ingredient (B) and 1-50wt.%, preferably 5-40wt.% ingredient (C). A semitransparent to transparent gelatinous hair dye having 5000-200000cPs viscosity is obtained by addition of the aforementioned blending ingredients.
The invention discloses a method for preparing saikoside from bupleurum longiradiatum. The method comprises the steps that a raw material is subjected to coarse grinding, and fed in from a feeding hopper; an extraction tank unit host rotates to slowly push the material from the front end of a unit backwards; an extraction solvent enters an extraction tank from a liquid inlet tube at the tail end of the unit, passes through the moving material from the back end of the tank, and flows towards the front end; and solid and liquid substances are contacted fully in an inverse motion, so that effective components in the medicinal material are extracted. Dregs are forcibly pushed to a dreg discharge port by a discharge transport and then discharged; a special juice squeezer squeezes the dregs; residual liquor in the dregs is squeezed out of a medicinal material tissue; and the content of the residual liquor in the dregs is reduced. The extraction efficiency is higher, and the extraction is more complete. The method adopts a continuous extraction tank unit for extraction, and is combined with a silica gel column chromatography for purification, so that a separating effect is better. Finished saikoside with a maximum yield of 4% and the content above 95% can be obtained.
NEW MATERIAL:The compound of formulaI(R is straight or branched chain lower alkyl; R' is 2- or 3-nitrophenyl; X and Y are O or S; n is 2 or 3; excluding the case that both X and Y are 0 and n is 2) characterized by the existence of cyclic ketal, semithioketal or dithioketal in the ester residue. EXAMPLE:Methyl 2, 2-trimethylenedioxypropyl 2,6-dimethyl-4-( 3-nitrophenyl )-1, 4-dihydropyridine-3,5-dicarboxylate. USE:A medicine having strong activity to increase the coronary and vertebral artery blood flow. It has excellent characteristics such as long duration, weak cardio inhibitory action, etc. PROCESS:The compound of formula is prepared by reacting the dihydropyridine derivative of formula II with 1,3-propanediol, etc. in a solvent such as benzene in the presence of an acid such as methanesulfonic acid at 0-150 deg.C for 1-24hr.
BACKGROUND: Obstructive sleep apnea (OSA), characterized by chronic intermittent hypoxia (CIH), is a prevalent condition that has been associated with various forms of cancer. Although some clinical studies suggest a potential link between OSA and lung cancer, this association remains uncertain, and the underlying mechanisms are not fully understood. This study investigated the role of the catecholamine-β-adrenergic receptor (βAR) and the NLRP3 inflammasome in mediating the effects of CIH on lung cancer progression in mice.
METHODS: Male C57BL/6 N mice were subjected to CIH for four weeks, with Lewis lung carcinoma cells seeded subcutaneously. Propranolol (a βAR blocker) or nepicastat (an inhibitor of catecholamine production) was administered during this period. Tumor volume and tail artery blood pressure were monitored. Immunohistochemical staining and immunofluorescence staining were employed to assess protein expression of Ki-67, CD31, VEGFR2, PD-1, PD-L1, and ASC specks in tumor tissues. ELISA was used to detect catecholamine and various cytokines, while western blot assessed the expression of cyclin D1, caspase-1, and IL-1β. In vitro tube formation assay investigated angiogenesis. NLRP3 knockout mice were used to determine the mechanism of NLRP3 in CIH.
RESULTS: CIH led to an increase in catecholamine. Catecholamine-βAR inhibitor drugs prevented the increase in blood pressure caused by CIH. Notably, the drugs inhibited CIH-induced murine lung tumor growth, and the expression of Ki-67, cyclin D1, CD31, VEGFR2, PD-1 and PD-L1 in tumor decreased. In vitro, propranolol inhibits tube formation induced by CIH mouse serum. Moreover, CIH led to an increase in TNF-α, IL-6, IL-1β, IFN-γ and sPD-L1 levels and a decrease in IL-10 in peripheral blood, accompanied by activation of NLRP3 inflammasomes in tumor, but these effects were also stopped by drugs. In NLRP3-knockout mice, CIH-induced upregulation of PD-1/PD-L1 in tumor was inhibited.
CONCLUSIONS: Our study underscores the significant contribution of β-adrenergic signaling and the NLRP3 inflammasome to CIH-induced lung cancer progression. These pathways represent potential therapeutic targets for mitigating the impact of OSA on lung cancer.
The invention relate to the structure and usage of antisense oligonucleotides, even according Sirtl gene design to prepared antisense oligonucleotides. The invention relate to the structure and usage of antisense oligonucleotides, even according Sirtl gene design to prepared antisense oligonucleotides. Adopting human lung carcinoma (A549) cell strain to select and evaluate the ten stripes of antisense oligonucleotides that was designed and prepared. Simultaneously checking the antisense oligonucleotide inhabitation to kinds of ordinary cancer cell strain when they cultured external. Experimental results show that the oligonucleotide sequences that described in right asked 2 has inhabitation to the growth of human lung carcinoma cell and stops the gene expression. The oligonucleotide also has inhabitation to breeding of hepatic carcinoma and prostate gland cancer. Therefore the invention is the placement antisense oligonucleotide structure to cancer and the invention is the new pattern drug to treat and decrease tumor and correlation hazard ness disease.
Promethazine hydrochloride, a phenothiazine derivative, is designated chemically as 10- [2-(Dimethylamino)propyl]phenothiazine monohydrochloride and has the following structural formula:

Promethazine hydrochloride is a racemic compound; the empirical formula is C17H20N2S HCl and its molecular weight is 320.88.

Promethazine hydrochloride occurs as a white to faint yellow, practically odorless, crystalline powder which slowly oxidizes and turns blue on prolonged exposure to air. It is freely soluble in water and soluble in alcohol. 

Each tablet for oral administration contains 12.5 mg, 25 mg or 50 mg promethazine hydrochloride, USP. The inactive ingredients include: lactose anhydrous, magnesium stearate, and microcrystalline cellulose. The 50 mg also contains D&C Red # 27 Lake.
A new and distinct variety of higher Basidiomycetes medicinal mushroom Ganoderma tsugae var. jannieae strain Tay-1 deposited under The Budapest Treaty with the Centralbureau voor Schimmelcultures (CBS) under Accession No. CBS 120394 is provided. Also provided are biomass and extracts of said mushroom rich in nutriceutical agents and biologically active compounds including proteins rich in essential amino acids and carbohydrates, vitamins, lipids rich in essential fatty acids, antioxidant agents, minerals, and melanin. The biomass and extracts are obtained from the fruiting bodies or the mycelial biomass, preferably a pure submerged mycelial culture. Compositions comprising biomass or extract are formulated into food products, beverages and cosmetic products, and may be used in therapy of NF-&kappav;B-dependent diseases.
OBJECTIVE: Individuals with Down Syndrome (DS) exhibit a higher susceptibility to infections, suggesting potential immunological alterations within this population. Consequently, this study aims to assess the immune response profile in children with DS to identify potential immune dysfunctions associated with recurrent infections.
METHODS: The authors conducted a retrospective analysis involving 49 DS patients, examining various epidemiological, clinical, cytogenetic, and laboratory variables. The study's sample comprised patients aged 2-20 years, with a predominance of males. These patients were categorized into two groups based on the presence or absence of recurrent infections, as indicated by the Jeffrey Modell Foundation alert signs.
RESULTS: Immunoglobulin (Ig) A, G, and M levels were deemed normal, although individuals with DS experiencing recurrent infections exhibited significantly lower IgA levels. Additionally, CD3, CD4, CD8, and CD19 lymphocyte counts were found to be within normal ranges, with no significant differences between the two groups. While overall data indicated normal seroconversion levels of pneumococcal polysaccharide antibodies, a notable impairment in seroconversion was observed among DS patients with recurrent infections compared to those without such infections.
CONCLUSION: The deficiency of anti-polysaccharide antibodies in individuals with DS may constitute an important immunological comorbidity. Therefore, it warrants further investigation, particularly among individuals with recurrent infections.
This study adopts a prospective cohort study. The expected recruitment time for all participants is 6 months, and all cases are cases who would receive magnifying endoscopy examination. The extent of atrophy and the presence of early gastric cancer are determined under magnifying endoscopy. Cases are chose into the gastric cancer group and atrophic gastritis group in a 1:1 ratio. There are 16 cases of intestinal type of gastric cancer under the background of atrophic gastritis, and 16 cases of atrophic gastritis without gastric cancer matched according to gender, age, and degree of gastric atrophy, totaling 32 cases. Analyze the characteristics of early gastric cancer under endoscopy, investigate the changes in microbiota and metabolomics of intestinal type of gastric cancer under the background of atrophic gastritis, and explore the relevant mechanisms.
Vaccines of the invention include at least four influenza virus strains. In some embodiments, the vaccines are produced in cell culture rather than in eggs. In some embodiments, the vaccines include an adjuvant. In some embodiments, the vaccines are not split or whole virion vaccines, but are live or purified glycoprotein vaccines. In some embodiments, the vaccines contain substantially the same mass of hemagglutinin (HA) for each of the influenza virus strains. In some embodiments, the four strains will include two influenza A virus strains and two influenza B virus strains ('A-A-B-B'). In other embodiments, the four strains will include three influenza A virus strains and one influenza B virus strain (`A-A-A-B').
The best treatment technique for pilonidal sinus disease (PSD) is still controversial. While some researchers prefer minimally invasive methods, some researchers prefer surgical treatment. The most important concern in surgical treatment options is the prolongation of the disease recovery time and recurrence of the disease. Complications that may develop after treatment prolong the treatment period. The aim of this prospective, randomized study was to compare the results of the widely used Limberg and Karydakis flap operations in recent years. The parameters that will be used in the comparison will be an infection, recurrence and wound decomposition.
PURPOSE: A composition containing soybean fermentation is provided to ensure antibacterial effect and prevent and treat food poisoning. CONSTITUTION: A composition for preventing and treating food poisoning contains soybean fermentation as an active ingredient. The soybean fermentation is obtained using Kimchi lactic acid bacteria. The Kimchi lactic acid bacteria is Lactobacillus plantarum, Leuconostoc kimchii, Leuconostoc citreum, Leuconostoc mesenteroides, Lactobacillus sakei Kimchi lactic acid bacteria. The food poisoning is caused by Staphylococcus aureus, Shigella flexneri, or Salmonella typhimurium. The composition additionally contains pharmaceutically acceptable carrier or excipient.
Patients randomized to this arm will receive N-Acetylcysteine, at a standard dose titrated to 2400 mg. They will receive NAC in addition to the medication regimen they are on at enrollment.
The invention discloses a porcine epidemic diarrhea virus attenuated vaccine strain. The porcine epidemic diarrhea virus attenuated vaccine strain is an attenuated vaccine obtained by PEDV/CH/NB/2014 passage attenuation and has an accession number of CGMCC No. 13299. The invention also discloses a use of the attenuated vaccine strain NB120 in prevention of porcine epidemic diarrhea diseases and the use belongs to the field of biotechnology. The attenuated vaccine strain NB120 can be processed to form a single vaccine or a multi-vaccine and the vaccine can effectively prevent porcine epidemic diarrhea diseases. The attenuated vaccine strain NB120 has the advantages of good safety and good immunogenicity. After applying to a sow or piglet, the vaccine strain can produce protective immune response to a prevalent strain of porcine epidemic diarrhea virus and thus the vaccine strain can effectively prevent infection caused by the prevalent strain of porcine epidemic diarrhea virus, can reduce a disease loss and has a good application prospect.
The microtubule-associated protein tau forms disease-specific filamentous aggregates in several different neurodegenerative diseases. In order to understand how tau undergoes misfolding into a specific filament type and to control this process for drug development purposes, it is crucial to study in vitro tau aggregation methods and investigate the structures of the obtained filaments at the atomic level. Here, we used the tau fragment dGAE, which aggregates spontaneously, to seed the formation of full-length tau filaments. The structures of dGAE and full-length tau filaments were investigated by magic-angle spinning (MAS) solid-state NMR, showing that dGAE allows propagation of a chronic traumatic encephalopathy (CTE)-like fold to the full-length tau. The obtained filaments efficiently seeded tau aggregation in HEK293T cells. This work demonstrates that in vitro preparation of disease-specific types of full-length tau filaments is feasible.
OBJECTIVE: We present low-level mosaic trisomy 14 at amniocentesis.
CASE REPORT: A 37-year-old, gravida 2, para 1, woman underwent amniocentesis at 18 weeks of gestation because of advanced maternal age. This pregnancy was conceived by in vitro fertilization and embryo transfer (IVF-ET). Amniocentesis revealed a karyotype of 47,XX,+14 [4]/46,XX [27], consistent with 12.9% mosaicism for trisomy 14. Simultaneous array comparative genomic hybridization (aCGH) analysis on the DNA extracted from uncultured amniocytes revealed the result of arr (1-22, X) × 2 with no genomic imbalance. Prenatal ultrasound findings were unremarkable. She was referred for genetic counseling at 21 weeks of gestation and was offered expanded non-invasive prenatal testing (NIPT) which was positive for trisomy 14. At 24 weeks of gestation, she underwent repeat amniocentesis which revealed a karyotype of 47,XX,+14 [2]/46,XX [26], consistent with 7% mosaicism for trisomy 14. The parental karyotypes were normal. Simultaneous aCGH analysis on the DNA extracted from uncultured amniocytes revealed no genomic imbalance. Polymorphic marker analysis excluded uniparental disomy (UPD) 14. Interphase fluorescence in situ hybridization (FISH) analysis on 104 uncultured amniocytes detected no trisomy 14 cell. At 35 weeks of gestation, a 2315-g phenotypically normal baby was delivered. The umbilical cord and placenta had the karyotype of 46, XX (40/40 cells). aCGH analysis on the DNA extracted from peripheral blood and buccal mucosal cells at the age of three months revealed no genomic imbalance. The neonate was normal in phenotype and development during postnatal follow-ups.
CONCLUSIONS: Low-level mosaic trisomy 14 at amniocentesis can be associated with cytogenetic discrepancy between cultured amniocytes and uncultured amniocytes, perinatal progressive decrease of the trisomy 14 cell line and a favorable fetal outcome.
<P>PROBLEM TO BE SOLVED: To provide a polymeric composition comprising a therapeutic agent in a crystalline phase and to provide a method for forming the same.  <P>SOLUTION: The polymeric composition comprises the therapeutic agent. The polymeric composition comprises at least one kind of therapeutic agent encapsulated in at least one kind of biocompatible polymer. At least a part of the therapeutic agent present in the polymeric composition is crystalline. At least the one kind of biocompatible polymer forms a substantially continuous polymeric matrix with at least the one kind of therapeutic agent encapsulated in the polymeric matrix. Otherwise, at least the one kind of biocompatible polymer forms polymeric particles with at least the one kind of therapeutic agent encapsulated in the polymeric particles.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Group 3 will receive a maximum of 3, one-month courses of prednisone (20 mg daily x 1 week, 10 mg daily x 1 week, 5 mg x 2 weeks). These will be administered based on sequential semen analyses. If a semen analysis demonstrates a drop in concentration from a prior analysis or if it shows a 0 concentration, the course will be administered.
BACKGROUND: Non-hypervascular hypointense nodules (NHHNs) can transform into hypervascular hepatocellular carcinoma (HCC) during the long-term follow-up. However, the risk factors for NHHN hypervascular transformation in chronic hepatitis B virus (HBV)-infected populations are unknown. This study assessed the predictive value of gadoxetic acid-enhanced magnetic resonance imaging (MRI) for HCC development in patients with chronic HBV infection.
METHODS: A total of 86 patients with HBV infection who underwent gadoxetic acid-enhanced MRI at the First Affiliated Hospital of Sun Yat-sen University between January 2011 and July 2019 and were followed up for 2 years were retrospectively reviewed. Imaging features, including cirrhosis, steatosis, and NHHNs, were collected. Radiomics features were extracted from the entire liver. The HCC development predictive models were built based on each patient's clinical data, MRI features, and radiomic features. We then collected the qualitative and quantitative features of each NHHN and investigated the risk factors of hypervascular transformation.
RESULTS: Thirteen patients developed HCC within two years. The risk factors for HCC development in patients with chronic HBV infection included older age, cirrhosis, and NHHNs. The MRI, radiomics, and integrated models developed all had an area under the curve (AUC) above 0.8. The potential risk factors for hypervascular transformation of NHHNs were the diameter of the NHHN (OR = 1.69, 95% CI:1.23, 2.32, P = 0.001) and the signal intensity (SI) ratio of the NHHN to the liver in the hepatobiliary phase (HBP SI ratio*10, OR = 0.36, 95% CI:0.11, 0.85, P = 0.044). The AUC of the hypervascular transformation model was 0.846 (95% CI:0.719, 0.972).
CONCLUSION: In chronic HBV infection population, patients with older age, cirrhosis and NHHNs are more likely to develop HCC within two years. Models based on these factors or radiomic features can effectively predict HCC development. The diameter of the NHHNs and the signal intensity ratio of NHHN to the liver in the hepatobiliary phase are potential risk factors for the hypervascular transformation of NHHNs.
This study was an open-label randomized efficacy and safety pilot trial in patients with acute heart failure (AHF) and hypertension (systolic blood pressure \[SBP\] ≥160 mm Hg) requiring parenteral antihypertensive therapy. Eligible patients were randomized to receive clevidipine or standard of care (SOC) intravenous antihypertensive treatment in an open-label manner in a ratio of 1:1. At the time of randomization, a patient-specific, prespecified SBP target range was determined and be recorded, prior to study drug treatment. Information on the dosing regimen, use of additional or alternative agents and transition to oral therapy if needed is detailed in the study 'ARM' and 'INTERVENTION' sections.

A Data Safety Monitoring Board was utilized periodically throughout the study to monitor the safety of patients. Adverse events were assessed for 7 days post-study randomization or hospital discharge, whichever occured first. Serious adverse events (SAEs) were assessed for 30 days following study randomization. Subjects were contacted by telephone or in person up to 5 days after their 30-day time point to determine if any SAEs occurred following study drug treatment and to follow up on the Heath Economic assessments.
The invention relates to a flexible dispensing container for applying hair fibre or concealer, not suitable for other powder products, and belongs to the hairdressing industry. The invention comprises: a flexible part, called a flexible dispensing container (1), which houses the hair fibre. Said part is joined to an immovable, fixed, quantity-regulating filter (2) into the upper part of which is inserted an upper, movable, quantity-regulating filter (3) that rotates on the immovable filter. The filters have a diameter of approximately 1.5 cm and are cylindrical. By means of both filters, the fibre is dispensed according to quantity levels, according to the hair loss. There are three quantity levels: level 1 (7), level 2 (8) and level 3 (9). The filters comprise 8 and 12 holes (4, 5) which, when the quantity level is chosen, produce a combination of holes, the position and opening thereof causing the hair fibre to be applied to each of the individual's hairs, in the desired area.
The first part of the study treatment or "first strike" involves 12-18 weeks of combined therapy with LHRH analog and one of the new hormonal agents (NHAs). Participants will complete the "first strike" at week 13 if their PSA has reduced \>90%; otherwise they will complete a total of 18 weeks of therapy. The second part of the treatment or "second strike" involves 4 cycles docetaxel and LHRH analog. The "second strike" will start immediately after the "first strike". MRI guided prostate biopsy will be performed after "second strike". For patients with positive prostate biopsy or detectable PSA, the "second strike" will be consolidated with 4-6 additional cycles of docetaxel plus 6 doses of tislelizumab at 200 mg, given IV once every 3 weeks. For patients with undetectable PSA at year 3 from study enrollment, LHRH analog can be discontinued.
In both interventional groups, Sevoflurane is used as an inhalational agent, in 0.5-1.5% age-adjusted MAC (Minimal Alveolar Concentration). As explained above, dexmedetomidine is infused with syringe pump, and concentration is adjusted so that Bispectral index (BIS) is maintained as 40-60, which means that the patients are maintained in general anesthesia. Dexmedetomidine is loaded for 10 minutes in 1mcg/kg, and then infusion rate is set between 0.4 to 0.6mcg/kg/hour for this study. If bradycardia or hypotension develops due to remifentanil infusion, the infusion rate could be reduced, or inotropic, vasopressor, anticholinergic agents can be used (ephedrine, atropine, etc.) to correct the side effects of the drug, or the drug infusion can even be ceased. At the end of the surgery when skin closure starts, dexmedetomidine infusion will be stopped.